Dental pulp stem cells and hydroxyapatite: a promising combination for maxillary bone regeneration
Luchman NA., Megat Abdul Wahab R., Zainal Ariffin SH., Yazid F., Nasruddin NS., Lau SF.
Animal Study, published in BMC Oral Health (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- BMC Oral Health (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41680705
- PMCID
- PMC12997732
- DOI
- 10.1186/s12903-026-07822-9
Abstract (original English)
BACKGROUND: Stem cells from human exfoliated deciduous teeth (SHED) and dental pulp stem cells (DPSC) exhibit significant potential for bone regeneration therapies. However, the optimal scaffold material for maximising their osteogenic potential remains unclear. AIM: This study investigated the comparative efficacy of hydroxyapatite (HA) and polycaprolactone (PCL) scaffolds in supporting SHED and DPSC proliferation and osteogenic differentiation for maxillary bone regeneration. METHODS: Cells were extracted from the dental pulp of deciduous and permanent teeth using enzymatic digestion and cultured until passage three. Characterisation of SHED and DPSC was conducted using morphological observation, stemness markers, proliferation analysis, and an alkaline phosphatase (ALP) assay. SHED and DPSC were then cultured on HA and PCL scaffolds, and in vitro cell proliferation and osteogenic potential (FESEM morphological analysis, ALP-specific activity, and osteoblast markers) were determined prior to in vivo transplantation. In vivo study involved the transplantation of cells with scaffolds into an artificial bone defect of 4 mm length and 1.5 mm depth in the rat’s left maxilla. Three-dimensional analysis via micro-computed tomography (micro-CT) and histological evaluations were performed six weeks post-transplantation. RESULTS: Characterised SHED and DPSC populations displayed mesenc
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.